A substantial number of high-risk prostate cancer patients at our clinic (approximately 100 patients) underwent staging exclusively with prostate-specific membrane antigen positron emission computer tomography (PSMA-PET/CT), which further constrains the analysis due to its inherent differences from conventional staging methods. This evidence concerns the gene FOLH1 and Familial prostate cancer.